This stock no longer trades (delisted May 11, 2026)

Delisted / no longer publicly traded (per market data provider) Everything below is based on the last available data — treat it as historical, not a live read.

Deep Value: cash covers more than 100% of the stock price

This company holds roughly $66M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Kezar Life Sciences

KZR

Biotechnology · Healthcare

Price

$7.29

+0.00 (+0.00%)

Market Cap

$53.9M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count falling — buybacks

−86.1% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 52.8M (2021) → 7.3M (2025)

Winston Score History

The full picture

Kezar Life Sciences is a small biotechnology company that discovers and develops new medicines for serious diseases where the immune system attacks the body, such as lupus and other autoimmune conditions. Its lead drug candidate, zetomipzomib, is designed to quiet overactive immune cells without shutting down the entire immune system. The company focuses on patients who have not responded well to existing treatments.

Kezar makes no product revenue yet because its drugs are still in clinical trials. It operates primarily in the United States and funds its research through cash reserves and occasional stock offerings, which is typical for early-stage biotech companies. With a market cap of roughly $100 million and deeply negative returns on capital, the company's survival depends on its clinical trial results — positive data could attract a partnership or acquisition, while a trial failure would put significant pressure on its remaining cash runway.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+65.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$34M/ year

↓ Declining (-49% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

17.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~2 years

$66M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$66M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-63.1%

Weak — -63.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.02

Conservative — low debt load (0.02)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial